PDRN

What it is

PDRN (polydeoxyribonucleotide) is a mixture of low molecular weight DNA fragments (typically 50–1,500 base pairs) extracted from salmon or trout sperm cells, purified to high standards through processes that remove protein and other contaminants. The DNA fragments themselves are biologically active signaling molecules, not the building blocks of new DNA.

PDRN was developed in Italy by Mastelli s.r.l. starting in the 1950s and has been in clinical use in Italy and several other countries for decades. It received approval in Italy and South Korea for various wound healing and tissue regeneration indications. Over 100 clinical trials have been published, primarily from Italian and Korean research groups. PDRN is not FDA-approved in the US; clinical use here is through licensed compounding pharmacies sourcing high-quality preparations.

The salmon/trout source is not arbitrary — these species’ DNA structure shares high homology with human DNA, which appears to optimize the activity of the resulting fragments at human receptors. The molecular weight range of the fragment mixture is also tightly controlled, as the biological activity is fragment-size-dependent.

Mechanism of action

PDRN’s mechanism centers on adenosine A2A receptor activation, with secondary contributions from nucleotide salvage:

• Adenosine A2A receptor agonism: the DNA fragments are partially hydrolyzed in tissue to release adenosine and adenine derivatives, which bind A2A receptors expressed on multiple cell types including endothelial cells, fibroblasts, and immune cells. A2A activation:
  • Promotes angiogenesis through VEGF upregulation
  • Stimulates fibroblast proliferation and collagen synthesis
  • Suppresses pro-inflammatory cytokine production
  • Supports tissue oxygen delivery to healing sites
• Nucleotide salvage pathway: the nucleotide building blocks released from PDRN provide raw materials for DNA repair and synthesis in cells with high turnover (regenerating tissue). This “salvage” mechanism may be particularly relevant where local nucleotide demand is high.
• Anti-inflammatory effects: independent of the A2A pathway, some studies suggest direct effects on inflammatory cell function.

Research findings

PDRN has one of the more substantial clinical evidence bases of any compounded peptide-class agent we prescribe.

Diabetic foot ulcers: multiple randomized trials in this challenging population have shown faster healing and higher complete healing rates with PDRN vs. standard care. A 2019 systematic review and meta-analysis confirmed clinically meaningful effects.

Osteoarthritis: intra-articular PDRN injection has been studied for knee osteoarthritis with results showing pain reduction and functional improvement comparable to or better than hyaluronic acid in some studies. Korean and Italian clinical practice has incorporated PDRN injection into orthopedic care.

Wound healing (non-diabetic): burn injuries, post-surgical wounds, chronic venous ulcers — multiple trials support faster healing and better cosmetic outcomes.

Aesthetic and dermatological use: PDRN has emerged as a major component of “salmon DNA” treatments in cosmetic medicine in Korea and is increasingly used elsewhere for skin remodeling, scar treatment, and as injectable mesotherapy.

Tendon and soft-tissue injury: early but encouraging evidence for chronic tendinopathy, with practitioner experience supporting use in difficult-to-treat cases.

How we use it at The Tide

We prescribe PDRN selectively for:

• Tendon and soft-tissue recovery, particularly for more severe or chronic injuries where BPC-157 monotherapy has been insufficient
• Post-procedure recovery protocols, including after surgical procedures and after orthopedic injection-based interventions
• Chronic wound healing scenarios, in coordination with the patient’s primary wound care provider
• Patients with slow-healing soft tissue injuries who have completed appropriate workup and conservative care

Standard dosing: 5.625 mg subcutaneously or intramuscularly, 2–3 times weekly, for 4–8 week cycles. Some protocols use intra-articular or local-injection routes for joint or tendon-specific applications, performed under appropriate clinical conditions.

What good response looks like: patients with chronic tendinopathy or wound issues typically report meaningful symptom improvement and visible healing progress within 3–4 weeks, with continued improvement through the cycle.

Side effects and contraindications

PDRN is generally well-tolerated across decades of clinical use. The most commonly reported issues:

• Mild injection site reactions, particularly with intra-articular use
• Transient post-injection joint discomfort following intra-articular administration
• Rare flu-like symptoms in the first few doses

Important contraindications:

• Salmon or fish allergy: while purification removes most protein, trace amounts may remain. Patients with documented salmon, trout, or significant fish allergy should not receive PDRN.
• Active malignancy: the regenerative and angiogenic effects raise theoretical concerns; we screen carefully and avoid use in patients with active or recent cancer.
• Pregnancy and breastfeeding: avoided in absence of safety data.
• Severe immunodeficiency: as a precaution, given the immune-modulating effects.

What we don’t yet know

Most of the clinical evidence base comes from Italian and Korean research groups; Western RCT replication is limited. Optimal dosing for various indications is somewhat empirical despite the substantial existing literature. The relative effectiveness of PDRN vs. other regenerative interventions (PRP, prolotherapy, biologics) is not well established in head-to-head studies. The minimum molecular weight threshold for biological activity is relatively well-characterized, but the exact contributions of different fragment-size populations within PDRN preparations are still being researched. We present PDRN to patients honestly: a peptide-class regenerative agent with substantial international clinical evidence, used selectively when standard care has plateaued.